share_log

Amgen | 8-K: AMGEN REPORTS SECOND QUARTER 2024 FINANCIAL RESULTS

Amgen | 8-K: AMGEN REPORTS SECOND QUARTER 2024 FINANCIAL RESULTS

安进 | 8-K：安进公布2024年第二季度财务业绩
美股SEC公告 ·  2024/08/07 04:10

Moomoo AI 已提取核心信息

Amgen reported strong Q2 2024 financial results with total revenues increasing 20% to $8.4 billion, driven by 26% volume growth partially offset by 3% lower net selling price. Product sales grew 20% to $8.0 billion, including $1.1 billion from rare disease products. Twelve products achieved double-digit sales growth, including Prolia, EVENITY, Repatha, and TEZSPIRE.GAAP earnings per share decreased 46% to $1.38, impacted by higher operating expenses including Horizon-related amortization. Non-GAAP EPS declined slightly by 1% to $4.97. Operating margin decreased to 23.7% GAAP and 48.2% non-GAAP. The company generated $2.2 billion in free cash flow.The company maintained its full-year 2024 guidance with total revenues expected between $32.8-33.8 billion. GAAP EPS is projected at $6.57-7.62 and non-GAAP EPS at $19.10-20.10. Amgen remains on track to achieve over $10 billion in debt reduction by end of 2025, having reduced debt by $2.0 billion year-to-date.
Amgen reported strong Q2 2024 financial results with total revenues increasing 20% to $8.4 billion, driven by 26% volume growth partially offset by 3% lower net selling price. Product sales grew 20% to $8.0 billion, including $1.1 billion from rare disease products. Twelve products achieved double-digit sales growth, including Prolia, EVENITY, Repatha, and TEZSPIRE.GAAP earnings per share decreased 46% to $1.38, impacted by higher operating expenses including Horizon-related amortization. Non-GAAP EPS declined slightly by 1% to $4.97. Operating margin decreased to 23.7% GAAP and 48.2% non-GAAP. The company generated $2.2 billion in free cash flow.The company maintained its full-year 2024 guidance with total revenues expected between $32.8-33.8 billion. GAAP EPS is projected at $6.57-7.62 and non-GAAP EPS at $19.10-20.10. Amgen remains on track to achieve over $10 billion in debt reduction by end of 2025, having reduced debt by $2.0 billion year-to-date.
安进公布了强劲的2024年第二季度财务业绩，总收入增长20%至84亿美金，主要受成交量增长26%的推动，部分被净售价下降3%所抵消。产品销售增长20%至80亿美金，其中罕见疾病产品占11亿美金。十二种产品实现了两位数的销售增长，包括Prolia、EVENITY、Repatha和TEZSPIRE。按公认会计原则（GAAP）计算，每股收益下降46%至1.38美金，受包括与Horizon相关的摊销在内的更高营业费用的影响。非GAAP每股收益轻微下降1%至4.97美金。营业利润率下降至23.7%（GAAP）和48.2%（非GAAP）。公司产生了22亿美金的自由现金流。公司维持其2024年全年的指导意见，预计总收入在328-338亿美金之间。GAAP每股收益预计在6.57-7.62美金之间，非GAAP每股收益预计在19.10-20.10美金之间。安进仍在按计划到2025年底实现超过100亿美金的债务削减，迄今为止已减少20亿美金的债务。
安进公布了强劲的2024年第二季度财务业绩，总收入增长20%至84亿美金，主要受成交量增长26%的推动，部分被净售价下降3%所抵消。产品销售增长20%至80亿美金，其中罕见疾病产品占11亿美金。十二种产品实现了两位数的销售增长，包括Prolia、EVENITY、Repatha和TEZSPIRE。按公认会计原则（GAAP）计算，每股收益下降46%至1.38美金，受包括与Horizon相关的摊销在内的更高营业费用的影响。非GAAP每股收益轻微下降1%至4.97美金。营业利润率下降至23.7%（GAAP）和48.2%（非GAAP）。公司产生了22亿美金的自由现金流。公司维持其2024年全年的指导意见，预计总收入在328-338亿美金之间。GAAP每股收益预计在6.57-7.62美金之间，非GAAP每股收益预计在19.10-20.10美金之间。安进仍在按计划到2025年底实现超过100亿美金的债务削减，迄今为止已减少20亿美金的债务。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    相关股票 相关股票
    代码 迷你走势 最新价
    Medicus Pharma
    MDCX
    -- 3.680
    Scilex Holding
    SCLX
    -- 0.354
    阿玛琳
    AMRN
    -- 0.612
    赛诺菲安万特
    SNY
    -- 54.500
    艾伯维公司
    ABBV
    -- 192.870
    解锁完整榜单
    重估中国资产
    继中国开创性的DeepSeek技术推出之后， 华尔街大行重估对中国市场的投资前景。
    热门讨论
    美联储暂停降息，你如何调整持仓？
    美联储宣布基准利率维持在4.25%—4.50%不变，符合市场预期。你会如何配置资产？ 展开
    联邦公开市场委员会新闻发布会，2025年1月29日